Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma

@article{Field2008RoflumilastAO,
  title={Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma},
  author={Stephen K. Field},
  journal={Expert Opinion on Investigational Drugs},
  year={2008},
  volume={17},
  pages={811 - 818}
}
  • S. Field
  • Published 2008
  • Medicine
  • Expert Opinion on Investigational Drugs
Background: Roflumilast is a selective phosphodiesterase-4 inhibitor with a broad range of anti-inflammatory actions. Studies in asthma and chronic obstructive pulmonary disease (COPD) have demonstrated that it can improve lung function and reduce inflammation. Objective: To review the clinical data on roflumilast in COPD and asthma. Methods: A PubMed search using the term roflumilast was used to identify articles, and the bibliographies of the identified articles were reviewed to identify… Expand
Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor
TLDR
If approved for general use, roflumilast is expected to find its role initially as a substitute for inhaled corticosteroids in the maintenance treatment of severe and very severe disease, particularly in patients who have frequent acute exacerbations, and perhaps as a supplementary drug when symptoms are not adequately controlled by current conventional COPD therapy. Expand
Comparison of the modes of action of Apremilast and Roflumilast
TLDR
The main aim of this thesis was to utilise cutting-edge biochemical techniques to discover whether Apremilast and Roflumilast work with different modes of action, and to suggest that Ap Remilast has distinct biological effects from that of R oflumILast and could represent a new therapeutic role for ApremILast in other diseases. Expand
Roflumilast Roflumilast N-oxide Pyridyl N-oxidationCYP 3 A 4 CYP 1 A 2 Urinary excretion
Correspondence: Stephen K Field Health Science Centre, Room 1437 University of Calgary, 3330 Hospital Dr Nw, Calgary, Alberta, Canada T2N 4N1 Tel +1 403 220 8722 Fax +1 403 283 6151 EmailExpand
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
TLDR
In addition to being a non-steroid, anti-inflammatory drug designed to target pulmonary inflammation, the preclinical pharmacology described in this review points to a broad functional mode of action of roflumilast that putatively addresses additional COPD mechanisms. Expand
Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease
TLDR
The potential of anti-inflammatory drugs that are currently in clinical development for COPD are considered and how these might reduce pulmonary inflammation in this disease is discussed. Expand
Novel treatments for asthma: Corticosteroids and other anti- inflammatory agents.
TLDR
A lot of compounds with anti-inflammatory effect are investigated in both pre-clinical and clinical studies, and there is still an unmet need to develop new agents in this field. Expand
Therapeutictargetsfornew therapyforcorticosteroid refractoryasthma
TLDR
The elucidation of the cause of the relative lack of corticosteroid response in this subgroup of asthmatic individuals may have important implications for other diseases, and present and future therapeutic and preventative strategies for cortiosteroid-refractory asthma are discussed. Expand
Therapeutic targets for new therapy for corticosteroid refractory asthma
TLDR
The elucidation of the cause of the relative lack of corticosteroid response in this subgroup of asthmatic individuals may have important implications for other diseases. Expand
Curious effects of fluorine on medicinally active compounds
TLDR
In this chapter, the critical significance of the strategic incorporation of fluorine(s) into therapeutic agents, which exerts “curious effects” of fluoride on potency and pharmacological properties is demonstrated by relevant examples and rationales are presented in each case. Expand
Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia
TLDR
An overview of the presently available scientific literature as well as recent meeting presentations suggests the potential uses of PDE10A inhibitors in CNS disorders, particularly schizophrenia. Expand
...
1
2
...

References

SHOWING 1-10 OF 83 REFERENCES
Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
TLDR
Roflumilast is a promising candidate for anti-inflammatory COPD treatment because it improved lung function and reduced exacerbations compared with placebo and long-term studies are needed to fully assess the effect on health-related quality of life. Expand
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
TLDR
Clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor. Expand
Efficacy and safety of roflumilast in the treatment of asthma.
TLDR
The results of this phase 2/3 study support the emerging role of roflumilast, 500 microg/d, in the treatment of asthma. Expand
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
TLDR
In severe, stable COPD, PDE4 inhibition with roflumilast produced a modest but significant improvement in lung function without changing the exacerbation rate or health status. Expand
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
TLDR
Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma. Expand
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
TLDR
Results from in vitro studies with roflumilast indicate that it has anti- inflammatory properties that may be applicable for the treatment of COPD, and this anti-inflammatory effect may in part explain the concomitant improvement in post-bronchodilator FEV1. Expand
Are phosphodiesterase 4 inhibitors just more theophylline?
TLDR
The introduction of PDE4 inhibitors represents an entirely new class of drugs for the treatment of respiratory disease and it is becoming increasingly apparent that theophylline is not working solely through PDE inhibition, as formerly assumed, and that this drug has other relevant pharmacologic activities that are likely to contribute to its efficacy. Expand
Theophylline for COPD
TLDR
A paper by Hirano et al in this issue of Thorax provides further support for the anti-inflammatory effects of theophylline in patients with COPD. Expand
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
TLDR
This study shows that a PDE4 inhibitor, roflumilast, effectively controls symptoms of allergic rhinitis and might be a future treatment option not only in allergic asthma but also in allergicrhinitis or the combination of the 2 diseases. Expand
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
TLDR
It is suggested that roflumilast has anti-inflammatory action and provides rationale for the investigation of roflarilast in asthmatic patients. Expand
...
1
2
3
4
5
...